CGRP-targeting medications reduce monthly migraine days by half in 28-61% of chronic migraine patients, with 41% converting from chronic to episodic migraine.
40.88% converted from chronic to episodic migraineAcross the reviewed studies, over 4 in 10 chronic migraine patients improved enough on anti-CGRP therapy to no longer meet the threshold for chronic migraine.
What the researchers found
Anti-CGRP monoclonal antibodies reduced monthly migraine days by 50% in 27.6-61.4% of chronic migraine patients across the reviewed studies. Conversion from chronic to episodic migraine occurred in 40.88% of cases. Between 29-88% of patients who were overusing acute medications successfully stopped. Obesity emerged as the main negative predictor of treatment response. Atogepant became the first gepant (oral CGRP receptor antagonist) to demonstrate significant reduction in monthly migraine days versus placebo. No single anti-CGRP monoclonal antibody showed clear superiority over others.
Why it matters
Chronic migraine affects millions of people and has limited treatment options, especially when medication overuse complicates the picture. This comprehensive review confirms that CGRP-targeting drugs represent a genuine breakthrough — they work, they're safe, and they help patients break the cycle of medication overuse. The finding about obesity as a predictor could help clinicians set realistic expectations.
How the study worked
The authors conducted a systematic review searching PubMed and Embase for randomized clinical trials and real-world studies on CGRP-targeting medications in chronic migraine patients. From 270 identified records, 19 studies met criteria for qualitative analysis. The review covered monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and gepants (atogepant), including combination therapy with onabotulinumtoxinA.
What this study cannot tell us
The review included only 19 studies for qualitative analysis from 270 identified records, and a formal meta-analysis was not performed. Heterogeneity in study designs, endpoints, and patient populations across the included studies limits direct comparisons. Evidence for combination therapy with onabotulinumtoxinA was described as lacking strong evidence. Real-world studies may have selection bias compared to randomized trials.
How to read the evidence
This is a systematic review synthesizing evidence from both randomized controlled trials and real-world studies, placing it high on the evidence hierarchy. However, it is a qualitative review without formal meta-analysis, and the included studies vary in design and quality.
When this study was published
Published in 2024, this review captures the most current evidence on CGRP-targeting therapies including newer gepants like atogepant.
The bigger picture
CGRP-targeting therapies represent the first migraine-specific preventive treatment class in decades. This review consolidates evidence showing they work across both controlled trials and real-world settings, which is significant because real-world patients are often more complex than trial participants. The emergence of oral gepants like atogepant alongside injectable monoclonal antibodies gives patients and doctors more options for personalized treatment.
Questions still open
- Why does obesity reduce the effectiveness of anti-CGRP medications, and can dosing adjustments compensate?
- How do long-term outcomes beyond 6-12 months compare across different CGRP-targeting therapies?
- Could combining gepants with monoclonal antibodies offer additional benefit over either approach alone?
Common questions
How effective are CGRP-targeting drugs for chronic migraine?
Who responds best to anti-CGRP migraine treatments?
Read the original research
CGRP-targeted medication in chronic migraine - systematic review.
The journal of headache and pain, 25(1), 51
Citation
Oliveira, Renato; Gil-Gouveia, Raquel; Puledda, Francesca. (2024). CGRP-targeted medication in chronic migraine - systematic review.. The journal of headache and pain, 25(1), 51. https://doi.org/10.1186/s10194-024-01753-y